Everything below concerns AEDG. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-07. Numbers and descriptions here follow the published literature rather than marketing material.
Published work on this compound consists mainly of in vitro experiments, animal studies, and small clinical investigations, a substantial share of which appeared in Russian-language journals. Sample sizes are generally small, control conditions differ between studies, and several endpoints rely on markers whose clinical meaning is itself debated. Reviews of the longevity field treat the peptide as an early example of telomerase-directed research rather than an established intervention. Regulatory treatment varies by country: some jurisdictions place it under prescription controls, others treat it as a laboratory material, and importation may be restricted regardless of local status.
Epitalon is a synthetic tetrapeptide whose sequence is alanine–glutamate–aspartate–glycine, commonly abbreviated AEDG. It was developed in Russia during the 1980s and 1990s by investigators associated with the St. Petersburg Institute of Bioregulation and Gerontology, who studied short peptides as regulators of gene expression and tissue function. The alternative spelling epithalon appears interchangeably in the literature, and the two names refer to the same molecule. Outside Russia it is encountered chiefly as a research chemical rather than a licensed medicine, and it holds no approval from the United States Food and Drug Administration or the European Medicines Agency.
The peptide is a synthetic analogue of epithalamin, a preparation extracted from bovine pineal glands. Investigators sought a short, chemically defined molecule that would reproduce some of the endocrine and gerontological observations attributed to the glandular extract. Proposed mechanisms centre on induction of telomerase activity, an effect reported in cultured human somatic cells in the early 2000s, together with influences on melatonin secretion and neuroendocrine regulation. Those mechanisms remain incompletely characterised, and the reported telomerase response has not been consistently reproduced by independent groups working in comparable systems.
Identity is normally established by reversed-phase high-performance liquid chromatography combined with mass spectrometry, a pairing that separates components and confirms molecular mass at once. Purity is quoted as a percentage from the chromatogram, and figures above ninety-five percent are a frequent commercial specification. Amino acid analysis or sequencing supplies further confirmation when required. Because many short peptides behave similarly under chromatography, retention time alone does not establish sequence; the mass measurement is what separates one tetrapeptide from another, and certificates should report both.
Short peptides such as AEDG are normally supplied as a freeze-dried solid and are kept dry, cold, and shielded from light. Holding at minus twenty degrees Celsius is common for the long term, while a refrigerator suffices for brief periods before use. The material takes up moisture to some degree, so containers should stay sealed and be allowed to reach room temperature before opening, which limits condensation on the contents. Repeated warming and cooling of a single container is discouraged because it admits water and can lower the amount of intact peptide.
| Property | Value | Notes |
|---|---|---|
| Peptide sequence | Ala-Glu-Asp-Gly | Often abbreviated AEDG in research literature |
| Common synonyms | Epithalon, epitalon, AEDG | Spelling variants refer to the same tetrapeptide |
| Molecular formula | C14H22N4O9 | Theoretical monoisotopic mass near 390.35 Da |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility class | Freely soluble in water | Hydrophilic peptide; dissolves in aqueous buffer |
Several names circulate for the same molecule, including epitalon, epithalone, epithalamin tetrapeptide, and the sequence code AEDG. A CAS registry number, 307297-39-8, is commonly cited for it, though catalogue entries should be checked against supplier documentation because mislabelled records occur. In its usual form the peptide carries free amino and carboxyl termini and is neither glycosylated nor lipidated. Researchers distinguish the defined tetrapeptide from epithalamin itself, a crude pineal preparation containing many peptides that is not chemically characterised.
Material supplied for laboratory use is normally a lyophilised white to off-white powder that dissolves readily in water and in isotonic saline. Lyophilised cakes are hygroscopic and should be equilibrated to room temperature before opening to limit condensation on the solid. Solutions are typically prepared at milligram-per-millilitre concentrations and divided into single-use aliquots, because repeated freeze–thaw cycles degrade short peptides. Aqueous solutions are far less stable than the dry powder, and identity is usually verified by mass spectrometry alongside purity estimation from reversed-phase high-performance liquid chromatography.
Epitalon is a synthetic linear tetrapeptide with the sequence alanine–glutamate–aspartate–glycine, abbreviated AEDG. Its molecular formula is C14H22N4O9 and the calculated mass is approximately 390.35 g/mol. The compound is made by solid-phase peptide synthesis rather than extracted from tissue, although early work described it as a short fragment of a peptide fraction obtained from bovine pineal extract. In the research literature the spelling epitalon and the variant epithalone both appear, while AEDG is the standard code used in peptide nomenclature.
Documentation accompanying research peptides usually includes a certificate of analysis listing the batch number, purity figure, and test methods applied. Buyers comparing suppliers should check whether the reported purity refers to chromatographic area or to a mass-balance calculation, because the two are not equivalent. Counter-ion content, residual solvents, and water content are sometimes omitted from such certificates even though they affect the actual peptide mass present. Independent verification through a second laboratory is the most direct way to confirm that a supplied material matches its label.
Purity assessment of peptide reagents normally relies on reversed-phase high-performance liquid chromatography. A gradient of acetonitrile in water with trifluoroacetic acid, paired with a C18 stationary phase, separates the target tetrapeptide from truncated sequences and deletion analogues. Detection at 214 nanometres exploits absorbance of the peptide backbone, since the molecule contains no aromatic residue. Results are expressed as a percentage of total peak area. Values above ninety-five percent are typical for research-grade material, although reporting conventions vary between suppliers.
Pornanong Aramwit (Thai: พรอนงค์ อร่ามวิทย์, RTGS: Phon-anong Aramwit; born 1970) is a pharmaceutical scientist, pharmacist, academic, and author. She serves as the Vice President in Research and Innovation at Chulalongkorn University (CU) and is also a member of the university's Council, Administrative Board of the National Innovation Agency, and the Royal Society of Thailand. Aramwit's research has encompassed protein research, including silk proteins, biomaterials, tissue engineering, and herbal substances. She has conducted clinical studies in nephrology and dermatology, focusing on materials for wound healing applications. She is an inventor of medical devices and in the food industry, and has received awards including the Merits of Leadership Award Grand Officer Level: Number of the cross 1156 from the UK, the Merits of Innovation Grand Officer Level: Number of the cross 30705 from France, and the Merits of Innovation Ribbon of Honor: Number of the cross 16834 from Belgium, as well as from the European Union and Spain. Additionally, she was awarded the 2018 Ambassador Award for Innovator with Outstanding Achievements, the 2019 Outstanding Professional Women Award by the Federation of Business and Professional Women of Thailand, and the 2024 National Outstanding Researcher Award by the National Research Council of Thailand (NRCT). Aramwit has authored more than 220 peer-reviewed articles, authored/co-authored several books and book chapters, and has 20 patents.
== Interactions == Elagolix has a number of potential drug interactions with other medications. Elagolix is a substrate of the cytochrome P450 (CYP450) enzyme CYP3A, and inhibitors and inducers of CYP3A4 may alter the metabolism of elagolix and increase or decrease its circulating levels. The strong CYP3A4 inhibitor ketoconazole has been found to increase peak levels of and total exposure to a single 150 mg dose of elagolix by about 2-fold. Paradoxically, rifampin, a strong inducer of CYP3A4 and other CYP450 enzymes, increased peak levels of and total exposure to a single 150 mg dose of elagolix as well. A single dose of rifampin increased peak levels of elagolix by 4.4-fold and total exposure by 5.6-fold, whereas continuous rifampin therapy increased peak levels of elagolix by 2-fold and total exposure by 1.7-fold. The use of elagolix at 200 mg twice per day concomitantly with rifampin is not recommended, whereas the concomitant use of elagolix at 150 mg once per day with rifampin should be limited to 6 months. No significant changes in exposure to elagolix were observed with concomitant administration of rosuvastatin (a substrate of OATP1B1, OATP1B3, and BCRP), sertraline (a moderate inhibitor of CYP2D6 and CYP2B6), or fluconazole (a strong inhibitor of CYP2C19 and a moderate inhibitor of CYP2C9 and CYP3A4). Elagolix is a substrate of the hepatic OATP1B1 transporter. Levels of elagolix have been found to be increased by 78% in people with a genotype characterized by reduced OATP1B1 transporter function.
=== Cardiovascular === Cardiomyopathy/heart failure - Angiotensin receptor blockers (ARBs), angiotensin converting enzyme inhibitors (ACEis), angiotensin receptor-neprilysin inhibitors (ARNis), beta-blockers, calcium channel blockers, loop diuretics, thiazide diuretics, mineralocorticoid receptor antagonists (MRAs), vasodilators Note that blood pressure control is also renally protective.
== V == Vagus nerve Cranial nerve X, responsible for parasympathetic control of the heart, lungs, and digestive tract. It also conveys sensory information from the viscera to the brainstem. Vasopressin Also known as antidiuretic hormone (ADH), it regulates water balance and blood pressure. In the brain, vasopressin influences social behavior and memory. Ventral A directional term meaning "toward the front" in the spinal cord or "toward the bottom" in the brain. Opposite of dorsal. Ventral horn The anterior portion of the spinal cord’s gray matter, containing motor neurons that project to skeletal muscles. Ventral stream A visual processing pathway ("what" pathway) that travels from the occipital lobe to the temporal lobe and is involved in object recognition and form representation. Ventral tegmental area (VTA) A midbrain structure containing dopaminergic neurons that project to the nucleus accumbens and prefrontal cortex, central to reward and motivation. Ventricles A set of interconnected cavities in the brain filled with cerebrospinal fluid (CSF), which cushions the brain and maintains intracranial pressure. Vestibular system The sensory system that contributes to balance, spatial orientation, and coordination of head and eye movements. Includes the semicircular canals and otolith organs. Vestibulo-ocular reflex (VOR) A reflex that stabilizes vision by producing eye movements in the opposite direction of head movement, allowing steady gaze.
Skeletal advancement to physically increase the pharyngeal airspace is often an option for craniofacial patients with upper airway obstruction and small lower jaws (mandibles). These syndromes include Treacher Collins syndrome and Pierre Robin sequence. Mandibular advancement surgery is one of the modifications needed to improve the airway; others may include reduction of the tongue, tonsillectomy, or modified uvulopalatoplasty.
Sources: en.wikipedia.org
Official U.S. Senate website Lathrop & Gage LLP – People – Eric S. Schmitt biography at his law firm Biography at the Biographical Directory of the United States Congress Financial information (federal office) at the Federal Election Commission Legislation sponsored at the Library of Congress Profile at Vote Smart "Voter Information for Eric Schmitt. November 4, 2008 Election". SmartVoter. League of Women Voters of California Education Fund. Retrieved April 6, 2009. Appearances on C-SPAN
=== Financing === In May 2016, Cerebras raised $27 million in a series A round led by Benchmark, Foundation Capital and Eclipse Ventures. In December 2016, the company raised a series B round led by Coatue Management. In January 2017, it raised a series C round led by VY Capital. In November 2018, Cerebras raised $88 million in a series D round, making the company a unicorn. Investors in this round included Altimeter, VY Capital, Coatue, Foundation Capital, Benchmark, and Eclipse. In November 2019, Cerebras raised $270 million in a series E round at a valuation of $2.4 billion. In November 2021, Cerebras raised $250 million in a Series F round, valuing the company at over $4 billion and bringing its total financing to $720 million. The Series F financing round was led by Alpha Wave Ventures and Abu Dhabi Growth Fund (ADG). In July, August, and September 2024, the company raised $85 million in a series F-1 round, selling shares for $14.66 each. In September 2025, the company raised $1.1 billion in a Series G round, selling shares for $36.23 each, or a valuation of $8.1 billion. In January 2026, the company raised $1.0 billion in a Series H round, selling shares for $89.01 each. In this round, Benchmark invested $225 million, while Alpha Wave and funds managed by Fidelity Investments each invested $100 million. On May 14, 2026, the company became a public company via the largest U.S. technology initial public offering since 2019, raising $5.55 billion by selling 30 million shares at $185 each and opening on Nasdaq at $350, valuing the company at $95 billion.
== Prevention == Passive recovery, instead of active recovery, is a form of rest that is recommended to be performed by athletes in between rigorous, intermittent exercise. With active recovery, time to exhaustion is much shorter because the muscles are deoxygenated at a much quicker rate than with passive recovery. Thus, if avoiding overtraining means preventing exhaustion, passive recovery or "static rest" is safest. "Five weeks of rest appreciably improve both performance and mood state, and there is growing evidence that a very low level of exercise will speed recovery." If active recovery is performed during intense exercise, an athlete may find themselves in a state of being overtrained. The gradual variation of intensity and volume of training is also an effective way to prevent overtraining.
In contrast to product requirements or other laws that hinder market access, the Court of Justice developed a presumption that "selling arrangements" would be presumed to not fall into TFEU article 34, if they applied equally to all sellers, and affected them in the same manner in fact. In Keck and Mithouard two importers claimed that their prosecution under a French competition law, which prevented them selling Picon beer under wholesale price, was unlawful. The aim of the law was to prevent cut throat competition, not to hinder trade. The Court of Justice held, as "in law and in fact" it was an equally applicable "selling arrangement" (not something that alters a product's content) it was outside the scope of article 34, and so did not need to be justified. Selling arrangements can be held to have an unequal effect "in fact" particularly where traders from another member state are seeking to break into the market, but there are restrictions on advertising and marketing. In Konsumentombudsmannen v De Agostini the Court of Justice reviewed Swedish bans on advertising to children under age 12, and misleading commercials for skin care products. While the bans have remained (justifiable under article 36 or as a mandatory requirement) the Court emphasised that complete marketing bans could be disproportionate if advertising were "the only effective form of promotion enabling [a trader] to penetrate" the market.
Sources: en.wikipedia.org
Historically, PAHs contributed substantially to our understanding of adverse health effects from exposures to environmental contaminants, including chemical carcinogenesis. In 1775, Percivall Pott, a surgeon at St. Bartholomew's Hospital in London, observed that scrotal cancer was unusually common in chimney sweepers and proposed the cause as occupational exposure to soot. A century later, Richard von Volkmann reported increased skin cancers in workers of the coal tar industry of Germany, and by the early 1900s increased rates of cancer from exposure to soot and coal tar was widely accepted. In 1915, Yamigawa and Ichicawa were the first to experimentally produce cancers, specifically of the skin, by topically applying coal tar to rabbit ears. In 1922, Ernest Kennaway determined that the carcinogenic component of coal tar mixtures was an organic compound consisting of only carbon and hydrogen. This component was later linked to a characteristic fluorescent pattern that was similar but not identical to benz[a]anthracene, a PAH that was subsequently demonstrated to cause tumors. Cook, Hewett and Hieger then linked the specific spectroscopic fluorescent profile of benzo[a]pyrene to that of the carcinogenic component of coal tar, the first time that a specific compound from an environmental mixture (coal tar) was demonstrated to be carcinogenic.
==== Non-state actors ==== United Nations: The UN urged de-escalation between the belligerents and urged measures to protect civilians. European Union: The EU urged de-escalation and the implementation of the ceasefire declared on 15 July. It expressed its concern over Syria's sovereignty and integrity. Arab League: The General Secretariat of the Arab League strongly condemned the Israeli airstrikes on Syria, describing them as a blatant violation of the sovereignty of a fellow Arab League and UN member state and a clear breach of international law. The League characterized the attacks as acts of "bullying" that must not be tolerated by the regional or international community and called for their immediate cessation. It warned that the strikes aimed to sow chaos in Syria by exploiting recent unrest in Suwayda—events which the Syrian government itself denounced and pledged to investigate. The League expressed full solidarity with Syria, urging the government to defuse tensions through dialogue and inclusive national reconciliation. Gulf Cooperation Council: The council condemned Israeli attacks on Syria. The Muslim World League issued a statement expressing its full solidarity with Syria against any threats to its security, stability, and sovereignty, particularly attempts to sow discord among its communities or interfere in its internal affairs. The League voiced support for the Syrian government's efforts to protect all segments of the population, uphold civil peace, and enforce the rule of law.
=== South Africa === In South Africa learnerships to qualify as a Phlebotomy Technician are offered by many public and private educational institutions as well as by private academies owned up by pathology laboratories (such as Ampath Laboratories, Lancet, PathCare) and healthcare service providers (such as Netcare, South African National Blood Service). Some of the larger retail pharmacy chains offering in-store clinical services (such as Clicks, Dis-Chem) also provide training for aspirant phlebotomists. Certification can be obtained from a number of examination and testing institutions. To work as a phlebotomist in South Africa, registration with the Health Professions Council of South Africa (HPCSA) is required.
==== Elimination ==== Instead of by hepatic metabolism, atenolol is eliminated from the blood mainly via renal excretion. Atenolol is excreted about 40 to 50% in urine and 50% in feces with oral administration. Conversely, it is excreted 85 to 100% in urine unchanged and 10% in feces with intravenous administration. Only very small amounts of hydroxyatenolol and atenolol glucuronide are found in urine with atenolol. The elimination half-life of atenolol is about 6 to 7 hours. The half-life of atenolol does not change with continuous administration. With intravenous administration, atenolol levels rapidly decline (5- to 10-fold) during the first 7 hours and thereafter decline at a rate similar to that with oral administration. The elimination of atenolol is slowed in renal impairment, with the elimination rate being closely related to the glomerular filtration rate (GFR) and with significant accumulation occurring when the creatinine clearance rate is under 35 mL/min/1.73 m2. At a GFR of less than 10 mL/min, the half-life of atenolol increases up to 36 hours.
Selegiline, also known as L-deprenyl and sold under the brand names Eldepryl, Zelapar, and Emsam among others, is a medication which is used in the treatment of Parkinson's disease and major depressive disorder. It has also been studied and used off-label for a variety of other indications, but has not been formally approved for any other use. The medication, in the form licensed for depression, has modest effectiveness for this condition that is similar to that of other antidepressants. Selegiline is provided as a swallowed tablet or capsule or an orally disintegrating tablet (ODT) for Parkinson's disease and as a patch applied to skin for depression. Side effects of selegiline occurring more often than with placebo include insomnia, dry mouth, dizziness, anxiety, abnormal dreams, and application site reactions (with the patch form), among others. At high doses, selegiline has the potential for dangerous food and drug interactions, such as tyramine-related hypertensive crisis (the so-called "cheese reaction") and risk of serotonin syndrome. However, doses within the approved clinical range appear to have little to no risk of these interactions. In addition, the ODT and transdermal patch forms of selegiline have reduced risks of such interactions compared to the conventional oral form. Selegiline has no known misuse potential or dependence liability and is not a controlled substance except in Japan. Selegiline acts as a monoamine oxidase inhibitor (MAOI) and thereby increases levels of monoamine neurotransmitters in the brain.
Sources: en.wikipedia.org
Epitalon is a synthetic four-amino-acid peptide with the sequence alanine–glutamate–aspartate–glycine, also written AEDG. It was developed in Russian gerontology research and is studied for proposed effects on telomerase, melatonin regulation, and neuroendocrine function. It is not an approved pharmaceutical in the United States or the European Union.
No. Epithalamin is a peptide-rich extract prepared from bovine pineal glands, while epitalon is a short synthetic peptide designed as a defined analogue of it. The synthetic version was intended to provide a reproducible molecule with some of the same proposed biological activity.
Telomere elongation and telomerase activation have been reported in cultured human somatic cells, but evidence from living human subjects is limited and has not been independently confirmed at scale. Reported findings come largely from small studies with differing designs, so the question remains open rather than settled.
Reversed-phase high-performance liquid chromatography is run alongside mass spectrometry. The chromatogram separates components and gives a purity figure, while the mass spectrum confirms that the measured molecular mass matches the expected sequence. Neither measurement on its own is treated as sufficient.